ClinicalTrials.gg
RecruitingNCT07417410ALERTUpdated Mar 2, 2026

Analysis of DR Progression to Identify Risks and Need for Treatment

An observational study in Diabetic Retinopathy, sponsored by Association for Innovation and Biomedical Research on Light and Image. Recruiting at 1 site in Portugal. Open to participants aged 35 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Association for Innovation and Biomedical Research on Light and Image · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Ages
35 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image — 2 open to participants now, 3 under way, none of them phase 3. Diabetic Retinopathy · Association for Innovation and Biomedical Research on Light and Image.

Planned enrollment
2nd of 16
1,000 · median 81
Started
2025
with 1 other
Observational
16 of 18
2 open now
Registered
17th of 18
by date

Among the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, this one is the 2nd largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2025, is one of 16 observational ones, and was the 17th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 35 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, or all of them as a file.
02

Study summary

The goal of this observational study is to understand whether vascular and structural changes in the eyes caused by diabetes can help predict which people are more likely to experience worsening diabetic retinopathy (a diabetes-related eye disease) and how these eye changes are related to cardiovascular complications.

The study will include about 1,000 people with type 2 diabetes, aged 35 to 90 years, and will take place over twelve months. It may also include a retrospective component, where existing medical and imaging data collected from previous visits (within the last 1 to 5 years) will be analyzed.

The main questions it aims to answer are:

  • Can eye vessel and tissue changes, observed through modern imaging techniques and clinical data, help better describe and predict which cases of diabetic retinopathy will become more severe?
  • Can these same eye changes help predict the presence and risk of cardiovascular problems-such as heart disease or stroke-in people living with type 2 diabetes?
Read the detailed description

Diabetic Retinopathy (DR) is a leading cause of vision loss in adults with type 2 diabetes (T2D) and is associated with systemic complications, including cardiovascular disease. Early identification of patients at high risk of DR progression and cardiovascular events is critical to optimizing clinical management. Retinal imaging biomarkers, combined with clinical and demographic data, provide an opportunity to better understand disease mechanisms, predict progression of DR and associated cardiovascular complications, and guide personalized interventions.

The aim of this study is to investigate the influence of central versus peripheral retinal lesions on DR progression and staging, characterize associations between retinal biomarkers and cardiovascular risk factors and major adverse cardiovascular events (MACE), and contribute to the understanding of pathophysiological mechanisms underlying DR in T2D patients. The study will also generate a high-quality, harmonized database to support the development of artificial intelligence (AI) models.

This study aims to determine the extent to which central and peripheral retinal lesions, together with quantitative imaging biomarkers, contribute to the progression and staging of DR and the occurrence of cardiovascular complications in patients with T2D. Additionally, in the scope of the ALERT project (supported by Fundação para Ciência e Tecnologia (FCT); COMPETE2030-FEDER-00921900), the data of this clinical study will be used to create a harmonized, high-quality database for the development of exploratory interpretable artificial intelligence models for predicting DR progression and stage as well as predict the values of cardiovascular risk factors, and the risk of developing cardiovascular complications.

03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
35 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

1.000 participants with T2D will be included in this study, in a recruitment period of 12 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 2 diabetes according to the 1985 WHO criteria.
  • Age between 35 and 90 years.
  • Retrospective visit or referenced patients. For the retrospective visit, a documented follow-up of 1-5 years is required, with at least one clinical visit. For the referenced patients, it is required that they have either diabetic retinopathy at the baseline visit, the presence of at least one cardiovascular risk factor at the baseline visit, or cardiovascular complications at the baseline visit.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Previous laser photocoagulation or intravitreal injections (consider if were administered).
  • Presence of macular edema (CSME) with vision loss or requiring immediate treatment.
  • Proliferative diabetic retinopathy.
  • Any ocular surgery within the previous 3 months.
  • Renal Replacement Therapy (Hemodialysis, Peritoneal Dialysis).
  • Severe systemic illness, subject to investigator's judgment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in Diabetic Retinopathy Staging

    Change in score on the Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS DRSS; range 10-85; higher scores indicate worse severity), measured on Optos Ultra-Widefield Fundus Photography.

    Time frame: Baseline to 12 months

  2. Diabetic Retinopathy (DR) Progression, measured on the OPTOS Ultra-widefield Fundus Photography (UWF-FP)

    Defined as a ≥2-step worsening on the Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS DRSS)

    Time frame: Baseline to 12 months

  3. Proportion of participants with ≥15-letter loss in ETDRS Best-Corrected Visual Acuity (BCVA)

    ≥15-letter loss on the ETDRS BCVA chart (measured with Snellen or LogMAR charts converted to the ETDRS scale).

    Time frame: Baseline to 12 months

  4. Incidence of Major Adverse Cardiovascular Events (MACE)

    Incidence of myocardial infarction, ischemic stroke, or hospitalization for heart failure, extracted from medical history and confirmed by investigator.

    Time frame: Baseline to 12 months

Secondary outcomes

  1. Number of microaneurysms in the central ETDRS area (90°)

    Count of microaneurysms within the central ETDRS grading area (90 degrees), assessed by human graders on Optos Ultra-Widefield Fundus Photography images.

    Time frame: Baseline to 12 months

  2. Number of microaneurysms in the peripheral retina (90-200°)

    Count of microaneurysms in the peripheral retinal area (between 90 and 200 degrees), assessed by human graders on Optos Ultra-Widefield Fundus Photography images.

    Time frame: Baseline to 12 months

  3. Presence of hemorrhages in the central ETDRS area

    Presence of retinal hemorrhages within the central ETDRS grading area (90 degrees), identified by human graders on Optos Ultra-Widefield Fundus Photography. Reported as the percentage of affected eyes.

    Time frame: Baseline to 12 months

  4. Presence of peripheral retinal hemorrhages (90-200°)

    Presence of retinal hemorrhages in the peripheral retina (90-200 degrees), assessed through human grading of Optos Ultra-Widefield Fundus Photography images. Reported as the percentage of affected eyes.

    Time frame: Baseline to 12 months

  5. Presence of exudates in the retina

    Presence of hard exudates identified by human graders on Optos Ultra-Widefield Fundus Photography. Reported as the percentage of eyes displaying ≥1 exudate.

    Time frame: Baseline to 12 months

  6. Presence of cotton wool spots in the retina

    Presence of cotton wool spots identified by human graders on Optos Ultra-Widefield Fundus Photography. Reported as the percentage of affected eyes.

    Time frame: Baseline to 12 months

  7. Correlation between retinal microaneurysm count and glycated hemoglobin (HbA1c)

    Correlation between the number of microaneurysms identified on Optos Ultra-Widefield Fundus Photography and (HbA1c) levels obtained through clinical laboratory testing. Reported as a correlation coefficient (r).

    Time frame: Baseline to 12 months

  8. Retinal vessel density

    Quantitative vessel density measured using Optical Coherence Tomography Angiography. Expressed in inverse millimeters (mm-1)

    Time frame: Baseline to 12 months

  9. Correlation between retinal vessel density and systolic blood pressure

    Correlation between vessel density quantified using Optical Coherence Tomography Angiography and systolic blood pressure collected during clinical evaluation. Reported as a correlation coefficient (r).

    Time frame: Baseline to 12 months

  10. Abnormal intercapillary spaces (AIS) in the retina

    Count of abnormal intercapillary spaces assessed using Optical Coherence Tomography Angiography automated analysis tools. Expressed as the percentage of pixels associated with the presence of abnormal intercapillary spaces relative to the total number of pixels in the slab.

    Time frame: Baseline to 12 months

  11. Correlation between abnormal intercapillary spaces (AIS) and major adverse cardiovascular events (MACE)

    Correlation between the number of abnormal intercapillary spaces measured on Optical Coherence Tomography Angiography and the occurrence of (MACE). Reported as a correlation coefficient (r).

    Time frame: Baseline to 12 months

  12. Retinal venous calibre

    Mean venous calibre measured in micrometers (μm) through automated analysis of Color Fundus Photography images.

    Time frame: Baseline to 12 months

  13. Retinal vascular tortuosity

    Vascular tortuosity calculated from Color Fundus Photography images using validated image analysis algorithms.

    Time frame: Baseline to 12 months

  14. Microaneurysm turnover (MAT) over one year

    Number of microaneurysms appearing and disappearing over a one-year period, quantified through automated analysis of sequential Color Fundus Photography images.

    Time frame: Baseline to 12 months

  15. Retinal fractal dimension

    Fractal dimension of the retinal vascular network, calculated using an automated feature extraction applied to Color Fundus Photography images.

    Time frame: Baseline to 12 months

  16. Foveal Avascular Zone (FAZ) metrics

    Area of the foveal avascular zone measured in square millimeters (mm²) using Optical Coherence Tomography Angiography automated segmentation tools.

    Time frame: Baseline to 12 months

07

Study locations

1 of 1 sites recruiting
  • AIBILI-Clinical Trial Centre
    Portugal, Coimbra District 3000-548, Portugal
    Recruiting
08

References and documents

Publications

  • Cunha-Vaz J, Mendes L. Characterization of Risk Profiles for Diabetic Retinopathy Progression. J Pers Med. 2021 Aug 23;11(8):826. doi: 10.3390/jpm11080826. PubMed 34442470 ↗
  • Marques IP, Madeira MH, Messias AL, Santos T, Martinho AC, Figueira J, Cunha-Vaz J. Retinopathy Phenotypes in Type 2 Diabetes with Different Risks for Macular Edema and Proliferative Retinopathy. J Clin Med. 2020 May 12;9(5):1433. doi: 10.3390/jcm9051433. PubMed 32408522 ↗
  • Santos AR, Almeida AC, Rocha AC, Reste-Ferreira D, Marques IP, Cunha-Vaz Martinho A, Mendes L, Santos T, Lewis W, Cunha-Vaz J. CENTRAL AND PERIPHERAL INVOLVEMENT OF THE RETINA IN THE INITIAL STAGES OF DIABETIC RETINOPATHY. Retina. 2024 Apr 1;44(4):700-706. doi: 10.1097/IAE.0000000000004021. PubMed 38109709 ↗
  • Sato Y, Lee Z, Hayashi Y. Subclassification of preproliferative diabetic retinopathy and glycemic control: relationship between mean hemoglobin A1C value and development of proliferative diabetic retinopathy. Jpn J Ophthalmol. 2001 Sep-Oct;45(5):523-7. doi: 10.1016/s0021-5155(01)00380-x. PubMed 11583677 ↗
  • Silva PS, Cavallerano JD, Haddad NM, Kwak H, Dyer KH, Omar AF, Shikari H, Aiello LM, Sun JK, Aiello LP. Peripheral Lesions Identified on Ultrawide Field Imaging Predict Increased Risk of Diabetic Retinopathy Progression over 4 Years. Ophthalmology. 2015 May;122(5):949-56. doi: 10.1016/j.ophtha.2015.01.008. Epub 2015 Feb 19. PubMed 25704318 ↗
  • IDF Diabetes Atlas 9th edition. (2019). IDF Diabetes Atlas 9th edition 2019. In International Diabetes Federation Diabetes Atlas, Ninth Edition.
  • Marques, I., Mendes, L., & Cunha-Vaz, J. (2018). Noninvasive Multimodal Imaging of Diabetic Retinopathy (pp. 88-101). https://doi.org/10.1159/000487414
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 75 non-industry observational studies under Diabetic Retinopathy, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13. This study's planned 12 months is below that.

Counting every sponsor, half of 92 studies reached it within 28 months; a quarter within 12 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Feb 18, 2026
StartActual
Nov 3, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07417410
Lead sponsor
Association for Innovation and Biomedical Research on Light and Image
Collaborators
Fundação para a Ciência e a Tecnologia
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Nov 3, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Joana F Tavares, PhD
Contact
alert_4c@aibili.pt
239480137
Liliana C Soares, MsC
Contact
alert_4c@aibili.pt
239480115
Luís Mendes, PhD
study director · Association for Innovation and Biomedical Research on Light and Image

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion